Abstract: The present invention provides therapeutic molecules for combating sepsis. The invention provides proteins capable of improving survival through immunomodulation in post septicaemia in mammals and oligosaccharides, capable of immuno modulating inflammation in a mammal. The invention provides protein homologs of human HSP70 derived from nematode Setaria digitata and their recombinant forms and oligosaccharides and their role in immunomodulating inflammatory response in a mammal. The invention also provides a composition comprising therapeutic and/or prophylactic proteins and oligosaccharide molecules for immunomodulation in sepsis; and method for treating and/or preventing sepsis, MODS (multiple organ dysfunction syndrome) or septic shock in a mammal.

Abstract: A microfluidic analyser and a method of using the same is disclosed. The microfluidic analyser comprising a droplet generator, an analyte flow channel in fluid communication with said droplet generator at a first end, wherein said flow channel is configured to allow the droplets to flow in from the first end and exit from a second opposing end, said flow channel receiving at least one illumination channel positioned at a predetermined location between the first and the second end to excite contents of the droplets and said flow channel further comprising a plurality of receiving channels set at predetermined angles to an axis of the flow channel to interrogate at least one optical signal from the illuminated droplet traversing the flow channel and wherein said receiving channels terminate in a signal detector at the distal end away from the flow channel.

Abstract: A method of inhibiting neuroinflammation in neuron surrounding cells, includes a step of treating the neuron surrounding cells with at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof, to inhibit the neuroinflammation. A method of managing neuroinflammation or neuroinflammation mediated neurodegenerative disease or disorder in a subject in need thereof, includes administering at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof to the subject. A composition includes at least one tyrosine kinase inhibitor or at least one sirtuin-2 inhibitor optionally along with pharmaceutically acceptable excipient.

Abstract: The present disclosure relates to microfluidic cartridge for determining resistance or susceptibility of microorganism towards agent selected from a group comprising antibiotics, antiviral, antifungal, pesticide and insecticide. The disclosure further relates to a kit comprising microfluidic cartridge containing components selected from a group comprising growth media, agent, reagent, sensor and any combination thereof. The microfluidic cartridge and the kit described herein enables rapid and personalized determination of susceptibility or resistance of microorganisms towards agent. The disclosure also relates to an assay for determining the susceptibility or resistance of microorganisms towards agent employing the said microfluidic cartridge.

Abstract: A method of inhibiting neuroinflammation in neuron surrounding cells, includes a step of treating the neuron surrounding cells with at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof, to inhibit the neuroinflammation. A method of managing neuroinflammation or neuroinflammation mediated neurodegenerative disease or disorder in a subject in need thereof, includes administering at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof to the subject. A composition includes at least one tyrosine kinase inhibitor or at least one sirtuin-2 inhibitor optionally along with pharmaceutically acceptable excipient.

Abstract: The present disclosure is related to a microfluidic flow analyzer for pathological detection. The microfluidic flow analyzer comprises plurality of buffer channels, sample channel, central flow channel, plurality of exciting optical channels and plurality of receiving optical channels. The plurality of exciting optical channels and the plurality of receiving optical channels are placed at predetermined angle to the central flow channel. The plurality of exciting optical channels excite cell in the sample solution flowing through the central flow channel. The cell being excited produces one or more optical signals. The one or more optical signals are received by the plurality of receiving optical channels. The microfluidic flow analyzer comprises plurality of detectors placed on each of the plurality of receiving optical channels for detecting one of the one or more optical signals. The detected optical signal is sent to a computing unit for pathological detection.